Allspring Global Investments Holdings LLC Has $72.39 Million Stake in Cencora, Inc. (NYSE:COR)

Allspring Global Investments Holdings LLC lessened its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 10.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 322,092 shares of the company's stock after selling 35,864 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.17% of Cencora worth $72,386,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in COR. Pacer Advisors Inc. boosted its stake in Cencora by 6,855.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after purchasing an additional 2,035,679 shares during the period. Wellington Management Group LLP raised its position in Cencora by 7.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after purchasing an additional 338,452 shares during the last quarter. Nordea Investment Management AB raised its position in Cencora by 40.2% in the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock valued at $243,173,000 after purchasing an additional 308,773 shares during the last quarter. Two Sigma Advisers LP raised its position in Cencora by 21.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock valued at $368,771,000 after purchasing an additional 292,600 shares during the last quarter. Finally, State Street Corp raised its position in shares of Cencora by 3.8% during the third quarter. State Street Corp now owns 8,045,896 shares of the company's stock worth $1,810,970,000 after acquiring an additional 291,867 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of the firm's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the transaction, the chairman now directly owns 306,752 shares of the company's stock, valued at $74,283,064.32. This trade represents a 6.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,187 shares of company stock worth $17,790,912. Insiders own 10.80% of the company's stock.

Cencora Price Performance

NYSE:COR traded down $1.50 during trading hours on Friday, reaching $243.03. 1,277,896 shares of the company were exchanged, compared to its average volume of 1,327,143. The company has a market capitalization of $46.97 billion, a P/E ratio of 34.57, a P/E/G ratio of 1.49 and a beta of 0.49. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $262.26. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53. The business has a 50 day moving average of $238.70 and a 200 day moving average of $237.42.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Research analysts forecast that Cencora, Inc. will post 15.36 EPS for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Friday, February 14th. Cencora's payout ratio is 31.29%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Mizuho began coverage on Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price for the company. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Wells Fargo & Company boosted their target price on Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. UBS Group upped their price objective on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Finally, Robert W. Baird upped their price objective on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $277.90.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.